Sanofi has shared promising results from a mid-stage study of its investigational anti-CD40L antibody, frexalimab, in patients with relapsing forms of multiple sclerosis (MS). Affecting approximately ...

The McDonald criteria revisions provide a unified approach for diagnosing MS from pediatric to late-life presentations, said ...